Skip to main content
OpenTrials
Completed

NCT Number: NCT07701395

Acute Caffeine Intake and Velocity Metrics

The purpose of this study was to determine whether the acute ergogenic effects of caffeine differ according to the velocity metric used to assess strength performance against different relative loads. Thirteen resistance-trained men completed a triple-blind, randomized, placebo-controlled, crossover study. Participants ingested either caffeine (3 mg·kg-1) or a placebo 60 min before performing bench press and back squat exercises at 25%, 50%, 75%, and 90% of one-repetition maximum (1RM). Mean velocity (MV) and mean propulsive velocity (MPV) were simultaneously recorded using a linear position transducer

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Caffeine and Resistance Exercise

Age range

18 year–35 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá

Alcalá de Henares, Madrid, 28805, Spain

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 35 years.
  • Body Mass Index (BMI) < 25 kg/m².
  • Resistance-trained individuals (more than 6 months of structured training).
  • Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from exercising.
  • Participants must be able to perform the tests described in the following section.

Exclusion criteria

  • History of neuromuscular diseases, heart disease, or conditions that may affect liver or muscle metabolism.
  • Use of drugs, stimulants, or sports supplements that could interfere with the dietary supplement used in the study.
  • Sedentary habits (less than 150 minutes/week of moderate exercise).
  • Having undergone prolonged periods of physical inactivity in the 6 months prior to the study.
  • Engaging in strenuous exercise within 48 hours prior to the tests.• Failure to replicate the same food intake on both experimental days.
  • Consumption of caffeine or any other stimulant after 6 pm on the day before the tests, to avoid headaches, discomfort, or lethargy in regular caffeine consumers.

Treatment and study plan

Caffeine

Dietary Supplement

Acute caffeine intake (3 mg·kg-1)

Placebo

Dietary Supplement

Acute placebo intake (3 mg·kg-1 of maltodextrin)

Primary outcomes

  1. Velocity metrics against different relative loads of one-repetition maximum

    Time frame: Through study completion, an average of 3 weeks

    Measuring bar mean velocity (during propulsive and braking phases in m/s) and mean propulsive velocity (m/s of the propulsive phase) displacement of the concentric phase during bench press and back squat exercises at 25%, 50%, 75%, and 90%1RM.

Secondary outcomes

  1. Adverse effects

    Time frame: Through study completion, an average of 3 weeks

    perception of power, endurance, energy and exertion, as well as heart, muscular and gastrointestinal discomfort were measured using a 5-point scale, with scores ranging from 1 (lowest perception or absence of symptoms) to 5 (highest perception or severity).

Sponsors and collaborators

Lead sponsor

University of Alcala

Other

Registry information

Official study title

Acute Caffeine Ingestion Similarly Enhances Mean and Mean Propulsive Velocity During Resistance Exercise in Trained Men

Acronym: CAF+Vel

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jul 14, 2026
Registry last updated
Jul 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.